PTC THERAPEUTICS INC (PTCT)       41.49  +1.14 (+2.83%)

41.49  +1.14 (+2.83%)

US69366J2006 - Common Stock - After market: 41.49 0 (0%)


Fundamental Rating

3

Overall PTCT gets a fundamental rating of 3 out of 10. We evaluated PTCT against 631 industry peers in the Biotechnology industry. PTCT has a bad profitability rating. Also its financial health evaluation is rather negative. While showing a medium growth rate, PTCT is valued expensive at the moment.




Profitability

Profitability Rating

3

PTCT's Return On Assets of -33.71% is amongst the best of the industry. PTCT does better than the industry average Return On Assets of -44.83%.
PTCT has a Profit Margin of -76.28%. This is better than the industry average of -464.10%.

The profitability ratios for PTCT are negative, so there is not much use analyzing them.
The Piotroski-F score of PTCT is 2.00. This is a very weak score and indicates problems in health and profitability for PTCT.
VS Industry

ROA (-33.71%) VS Industry: 65% outperformed.

-950.38
52.28

Profit Margin (-76.28%) VS Industry: 75% outperformed.

-1,173,705.71
34,743.00

Valuation

Valuation Rating

0

The Price/Earnings Ratio is negative for PTCT. In the last year negative earnings were reported.

Also next year PTCT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
VS Industry

Growth

Growth Rating

6

PTCT shows a strong growth in Revenue. In the last year, the Revenue has grown by 41.53%.
Measured over the past 5 years, PTCT shows a very strong growth in Revenue. The Revenue has been growing by 45.46% on average per year.
PTCT is expected to show quite a strong growth in Revenue. In the coming 5 years, the Revenue will grow by 15.12% yearly.

The Earnings Per Share is expected to grow by 9.54% on average over the next 5 years.
The earnings per share for PTCT have decreased strongly by -15.28% in the last year.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is decreasing.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A -15.28% 16.41% 23% 21.92% 9.54%
Revenue45.46% 26.72% 41.53% 40.08% 28.81% 22.64% 15.12%

Health

Health Rating

2

A Current Ratio of 1.23 indicates that PTCT should not have too much problems paying its short term obligations.
PTCT has a Quick Ratio of 1.20. This is a normal value and indicates that PTCT is financially healthy and should not expect problems in meeting its short term obligations.
PTCT has a Altman-Z score comparable to the industry average, which is at -0.81.
Compared to an average industry Current Ratio of 6.16, PTCT is worse placed to pay its short term obligations than its industry peers. 93% of its industry peers have a better Current Ratio.

When comparing the Quick Ratio of PTCT to the average industry Current Ratio of 6.05, PTCT is less able to pay its short term obligations than its industry peers. 92% of its industry peers have a better Quick Ratio.
PTCT has a negative Debt to Equity ratio (-4.33), which implies it has negative shareholder equity as the company's liabilities exceed its assets. This could be considered a sign of high risk.
Based on the Altman-Z score of -1.42, we must say that PTCT is in the distress zone and has some risk of bankruptcy.
The Piotroski-F score of PTCT is 2.00. This is a very weak score and indicates problems in health and profitability for PTCT.
VS Industry

Quick Ratio (1.2) VS Industry: 8% outperformed.

0.02
84.53

Current Ratio (1.23) VS Industry: 7% outperformed.

0.02
85.09

Altman-Z (-1.42) VS Industry: 47% outperformed.

-135.10
443.02

Dividend

Dividend Rating

0

No dividends for PTCT!.

PTCT Daily chart

PTC THERAPEUTICS INC41.49

NASDAQ:PTCT (11/30/2022, 7:00:01 PM)+1.14 (+2.83%)

After market: 41.49 0 (0%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry Biotechnology
Earnings (Last) 10-27 2022-10-27/amc Earnings (Next) 02-20 2023-02-20
Ins Owners 0.8% Inst Owners 105.76%
Market Cap 2.98B Analysts 76
Valuation
PE N/A Fwd PE N/A
PEG (NY) N/A PEG (5Y) N/A
P/S 4.28 P/B N/A
EV/EBITDA -15.65
Dividend
Dividend Yield N/A Dividend Growth N/A
DP N/A Ex-Date N/A
Growth
EPS 1Y -15.28% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 19.05%
EPS Next Y 16.41% EPS Next 2Y 23%
EPS Next 3Y 21.92% EPS Next 5Y 9.54%
Revenue growth 1Y 41.53% Revenue growth 3Y 26.72%
Revenue growth 5Y 45.46% Revenue growth Q2Q 56.5%
Revenue Next Year 40.08% Revenue Next 2Y 28.81%
Revenue Next 3Y 22.64% Revenue Next 5Y 15.12%
Health
Current Ratio 1.23 Quick Ratio 1.2
Altman-Z -1.42 F-Score 2
Debt/Equity -4.33 WACC 8.43%
ROIC/WACC N/A
Profitability
ROA -33.71% ROE N/A
ROICexgc N/A ROIC N/A
PM -76.28% OM -47.63%
Asset Turnover 0.44

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA